

## Research Letter Submission

Word count

Abstract: 197

Text: 958

### Title:

**Acute Pulmonary Embolism in Critically Ill Patients with COVID-19**

### Author List

Madhura Manjunath, MD\*  
Department of Internal Medicine  
Berkshire Medical Center  
725 North St  
Pittsfield, MA 01201  
[mmanjunath@bhs1.org](mailto:mmanjunath@bhs1.org)

Julio Miranda, MD\* &  
Pulmonary and Critical Care

Liana Fraenkel, MD, MPH\* &  
Rheumatology/Clinical Research

Paul Mange Johansen, MA\* &  
Biostatistician

Blessing Phinney, MD, MPH\*  
Department of Internal Medicine

Georgianne Valli-Harwood, MD\*  
Department of Cardiology

Cynthia Callahan, MD\*  
Pulmonary and Critical Care

Hafez Alsmaan, MD\*  
Critical Care Medicine

David Oelberg, MD\*  
Pulmonary, Critical Care and Sleep Medicine  
Berkshire Medical Center  
[doelberg@bhs1.org](mailto:doelberg@bhs1.org)

&These authors contributed equally to this work

\*Affiliated with Berkshire Medical Center, Pittsfield MA

\*No existing conflict of interest

## Abbreviation List

COVID-19 – coronavirus disease 2019  
PCR – polymerase chain reaction  
RNA – ribonucleic acid  
ICU – intensive care unit  
SDU – step down unit  
DVT – deep venous thrombosis  
PE – pulmonary embolism  
IRB – institutional review board  
CFR – code of federal regulations  
BMI – body mass index  
BID – twice daily  
CT – computerized tomography  
mg – milligram  
PESI – pulmonary embolism severity index  
CTA – computerized tomography, angiography  
TID – three times daily  
N – number  
GI – gastrointestinal  
O<sub>2</sub> – oxygen  
SD – standard deviation  
BP – blood pressure  
HR – heart rate  
RR – respiratory rate  
WBC – white blood count  
Hgb – hemoglobin  
CRP – c-reactive protein  
BNP – brain natriuretic peptide  
INR – international normalized ratio  
aPTT – activated partial thromboplastin time  
GGO – ground glass opacities  
RV – right ventricle  
LV – left ventricle  
n/a – not applicable  
FEU – fibrinogen equivalent units

## Abstract

Since the discovery of the novel coronavirus (SARS-CoV-2) in December 2019, multiple characteristics have been reported, as our understanding of this new disease unfolds. One such association is its tendency to cause thromboembolic events, particularly venous thromboembolism<sup>1,2</sup>. In a four-week period during the initial spread of COVID-19 at a 300 bed community hospital in western Massachusetts, 23 patients who were PCR positive for SARS-CoV-2 RNA required treatment in either the intensive care unit (ICU) or intermediate/step-down unit (SDU). All patients were treated with standard DVT prophylaxis from the time of admission, except for two patients who were on full anticoagulation for chronic atrial fibrillation. Of the 23 patients, 7 (30%) were diagnosed with acute, clinically significant, pulmonary embolism (PE). Four of the 7 manifested evidence of acute cor pulmonale, one of whom succumbed as a direct consequence of a massive PE. Other markers were reviewed in the 7 patients to identify trends that could allow for early suspicion of PE in COVID-19 patients. Although D-dimer tended to rise during the hospitalization relative to the control group, the results were inconsistent, and there were no other meaningful distinguishing features between the groups at the time of admission.

## Methods

Starting in mid-March, we reviewed the number of patients who were critically ill from confirmed COVID-19 and required ICU or SDU level of care over a four-week period at Berkshire Medical Center in Pittsfield, MA. We compared the clinical features and laboratory test results of patients with and without PE. We were limited to descriptive analysis between the two groups given the small sample size. The study was approved by the institution's IRB. Informed consent was waived based on criteria outlined in 45 CFR 46.104(d)(4).

## Results

Of the 23 COVID-19 positive, critically ill, patients hospitalized during a four-week period at our institution, 7 (30%) were diagnosed with concomitant acute PE during their inpatient stay. The two groups (PE+, n=7; PE-, n=16), had similar features on admission (Table 1). All patients in both groups were either former or never smokers. Respiratory and gastrointestinal symptoms were the most common complaints, but the mean resting heart rate was noted to be modestly higher in the PE group (104 vs. 88). Both groups showed lymphopenia. Pro-BNP was higher in the PE group at the time of admission, but the comparison was limited by incomplete data for the two groups. D-dimer trended upward in the PE group compared to the control group during the hospitalization (Figure 1). Other risk factors for PE, including BMI, recent surgeries, and travel history were similar across both groups.

Twenty one of the 23 patients were treated with DVT prophylaxis using either subcutaneous unfractionated heparin (5000 units BID, n=11) or low molecular weight heparin (40 mg daily, n=10) starting at the time of admission, while two patients were maintained on their home regimen of novel oral anticoagulants for atrial fibrillation (both in the PE- group). Of the seven patients who developed acute PE, the mean time to diagnosis was 9.4 days following hospitalization. The mean Wells score for the PE+ group was 5.7 and the PE- group 4.2, indicating a lack of discrimination with use of Wells criteria in these two groups. The diagnosis of acute PE was confirmed by CT pulmonary angiography in 6 patients and by transthoracic echocardiography in one patient, who suddenly became hypotensive on day five with severe right ventricular dysfunction and a positive McConnell sign. Despite treatment with thrombolytic therapy (100 mg intravenous tissue plasminogen activator) he expired three days later with multi-organ failure secondary to obstructive shock.

Of the 6 surviving PE patients, four were stratified as having minor (low risk) and two as having submassive (intermediate risk) pulmonary emboli. The mean pulmonary embolism severity index (PESI) score among our 7 PE patients was 119, indicative of high risk of mortality and morbidity (class IV, 4 to 11.4% 30-day mortality risk). Five received anticoagulation with either therapeutic doses of Heparin or Enoxaparin and were later converted to oral anticoagulation. One patient was found to have small,

subsegmental PE on CTA, thought to be very low risk, and was maintained on prophylactic doses of subcutaneous Heparin (increased to 5000 units TID).

## **Discussion**

Our study adds to the growing recognition that patients with COVID-19 appear to be at high risk of developing PE. Since a search for PE was not conducted in all our patients admitted to the ICU, the 30% incidence of PE identified in this study may be an underestimate. The mechanism of hypercoagulability in these patients is not known, but the emergence of antiphospholipid antibodies and/or triggering of disseminated intravascular coagulation in critically ill patients have been suggested as possible mechanisms<sup>3,4</sup>. The latter is also supported by autopsy reports, which have shown the presence of frank hemorrhage along with small thrombi in sections of the lung parenchyma<sup>5</sup>.

In light of the growing incidence of acute PE in COVID-19 patients, despite standard DVT prophylaxis, intensified regimens of thromboprophylaxis may be indicated. D-dimer tended to rise during hospitalization in the PE group, which is consistent with studies correlating high D-dimer levels in patients at high-risk for PE<sup>6</sup>. However, the results were not consistent, so we could not conclude that initial or serial D-dimer assays could reliably predict who would subsequently develop PE and who would not.

The incidence of symptomatic PE in a general medical ICU is around 0.7-6%<sup>7</sup>, well below the 30% incidence reported in this series. Larger studies are needed to identify risk factors for PE and determine the level of anticoagulation required for specific subgroups. Meanwhile, clinicians should have a low threshold to suspect venous thromboembolism while treating patients with COVID-19 and consider routinely screening these patients and/or utilizing higher doses of thrombo-prophylactic regimens than the current standard for critically ill patients.

## **Acknowledgements**

MM, LF, and DO helped design the study based on the observations of GVH, HA, CC, JM, and DO in the ICU. Data collection was done through chart review by medical residents (see below) under the supervision of MM and BP. Analysis and interpretation of the data was aided by LF and PMJ. Drafting of the manuscript and the revisions were primarily done by MM and DO, with significant input from all other authors listed.

Medical residents involved with the chart review include Andrea Parra Corral, MD; Anoop Kumar, MD; Areej Khan, MD; Mintu John, MD; Muhammad Bilal, MD; Taroob Latef, MD; Xiaocao Xu, MD.

Mazen Ghani, MD with the Radiology department at Berkshire Medical Center reviewed the imaging to help us with readings and measurements.

## References

1. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? *European Heart Journal*. 2020; doi: 10.1093/eurheartj/ehaa254.
2. Xie Y, Wang X, Yang P, Zhang S. COVID-19 Complicated by Acute Pulmonary Embolism. *Radiology: Cardiothoracic Imaging*. 2020; 2(2): e200067.
3. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. *The New England Journal of Medicine*. 2020; doi: 10.1056/NEJMc2007575.
4. Porfidia A, Pola R. Venous thromboembolism in COVID-19 patients. *Journal of Thrombosis and Hemostasis*. 2020; doi: 10.1111/jth.14842.
5. Fox S, Akmatbekov A, Harbert JL, Li G, Brown JQ, Vander Heide RS. Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans. *BMJ*. 2020; doi: 10.1101/2020.04.06.20050575.
6. Aujesky D, Roy PM, Guy M, Cornuz J, Sanchez O, Perrier A. Prognostic value of D-dimer in patients with pulmonary embolism. *Thromb Haemost*. 2006; 96(04): 478-482.
7. Bahloul M, Chaari A, Kallel H, et al. Pulmonary embolism in intensive care unit: Predictive factors, clinical manifestations and outcome. *Ann Thorac Med*. 2010; 5(2): 97–103.

Table 1

Variable	COVID, PE+ (N = 7)	COVID, PE- (N = 16)
Age	46-75 (61.7)	54-81 (70.4)
Sex - N (%)		
Male	5 (71)	10 (63)
Medical history - N (%)		
Hypertension	5 (71)	9 (56)
Diabetes mellitus	2 (29)	7 (44)
Coronary artery disease	0	4 (25)
Congestive heart failure	0	3 (19)
Atrial fibrillation	0	3 (19)
Cancer/neoplasm	2 (29)	3 (19)
Obstructive lung disease	1 (14)	3 (19)
Chronic steroid use	0	2 (13)
Duration of symptoms in days - range (mean)	7-14 (8.86)	1-21 (6.88)
Clinical presentation - N (%)		
Dyspnea and cough	7 (100)	14 (88)
Chest pain	1 (14)	3 (19)
Fever/chills	6 (86)	11 (69)
GI symptoms	3 (43)	7 (44)
Leg swelling/pain	1 (14)	0
Supplemental O2 requirement on admission	6 (86)	13 (81)
Vitals on admission - Mean (SD)		
BMI	29 (3.9)	31 (7.8)
Temp (F)	100.4 (2.7)	100 (1.8)
Systolic BP	132 (17.2)	120 (29.2)
HR	104 (14.7)	88 (18.5)
RR	28 (12.3)	25 (7.0)
Initial lab data - Mean (SD)		
WBC	6.46 (3.0)	11.89 (12.7)
Hgb	14.29 (1.8)	12.61 (2.1)
Platelets	204 (108)	180 (60)
Creatinine	1.89 (2.6)	1.42 (1.1)
CRP	133.6 (55.8)	107.6 (57.5)
Ferritin	2349 (2210)	4057 (10403)
pro-BNP (PE+ N = 5; PE- N = 7)	5321 (10784)	943 (799)
Troponin-I	0.083 (0.1)	0.159 (0.4)
Pro-calcitonin	0.613 (0.9)	1.019 (1.7)
INR	1.11 (0.1)	1.17 (0.3)
aPTT	35.5 (10.9)	30.7 (5.0)
D-dimer	2.6 (3.0)	8.79 (10.8)
Fibrinogen	602 (198)	587 (166)

Imaging results - N (%)		
Infiltrates/GGO on CT chest	7 (100)	12 (75)
CTA with PE protocol	6 (86) - all positive	4 (25) - all negative
RV:LV size on CT > 0.9	4 (57)	n/a
Venous duplex	5 (71) - 1 positive	1 (6) - negative
Outcome - N (%)		
Expired	1 (14)	6 (38)
Still hospitalized	4 (57)	5 (31)
Discharged	2 (29)	5 (31)

## Figure 1 legend

Of the 7 PE+ patients, one had no D-dimer measurements and one had a single D-dimer measurement (patient 6); of the 16 PE- patients, two had no D-dimer measurements and two had a single D-dimer measurement (patients 13 and 14). Solid linear regression lines represent PE+ patients (N=5) and dotted linear regression lines represent PE- patients (N=12). Decreasing linear regression lines only occurred in PE- patients (2 of 12 = 17%). Increasing linear regression lines occurred in 80% (4 of 5) of the PE+ patients and 33% (4 of 12) of the PE- patients. The remaining linear regression lines were essentially flat, occurring in 20% (1 of 5) of the PE+ patients and 50% (6 of 12) of the PE- patients.

